Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecu...
Gespeichert in:
| Veröffentlicht in: | The Journal of clinical investigation 2021-09, Vol.131 (18), Article 152696 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 18 |
| container_start_page | |
| container_title | The Journal of clinical investigation |
| container_volume | 131 |
| creator | Franco, Aime T. Ricarte-Filho, Julio C. Laetsch, Theodore W. Bauer, Andrew J. |
| description | Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict clinical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients. |
| doi_str_mv | 10.1172/JCI152696 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A677401852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A677401852</galeid><sourcerecordid>A677401852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-c1aa12ee002d04495fff7bd4948aa711c0c7e6d67789c69ad41f83df6ff64e8e3</originalsourceid><addsrcrecordid>eNqNkl2LEzEUhoMobq1e-AdkQBBFZk1mkknmRliKH5WFwvpxG9LkpBOZJt1JZnX_vRm6li30YslFQs7zvjmcvAi9JPicEF59-LZYElY1bfMIzQhjohRVLR6jGcYVKVteizP0LMbfGBNKGX2KzmrKqrrBfIauVl6HDXgo4w60s04Xzndu7ZILPh-L1EGRBlBpCz4VwRbK3CivwRQ7ME6lIStSdzsEZwo9FYbn6IlVfYQXd_sc_fz86cfia3m5-rJcXFyWmvE2lZooRSqA3KTBlLbMWsvXhrZUKMUJ0VhzaEzDuWh10ypDiRW1sY21DQUB9Rx93PvuxvUWjM79DaqXu8Ft1XArg3LyuOJdJzfhRgpat0ywbPD2zmAI1yPEJLcuauh75SGMUVaMVy3FpBUZfb1HN6oH6bwN2VFPuLzIHWZI5InOUXmCmqabnw8erMvXR_z5CT4vA1unTwreHQkyk-Bv2qgxRrn8fvVwdvXrmH1zj-1A9amLoR-nEMSTpnoIMQ5gD-MmWE5ZlIcsZvbV_f85kP_DlwGxB_7AOtioHeT4HDCMMceM1aLKJ9wsXFJTO4sw-pSl7x8urf8Berf3Rw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572940198</pqid></control><display><type>article</type><title>Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Franco, Aime T. ; Ricarte-Filho, Julio C. ; Laetsch, Theodore W. ; Bauer, Andrew J.</creator><creatorcontrib>Franco, Aime T. ; Ricarte-Filho, Julio C. ; Laetsch, Theodore W. ; Bauer, Andrew J.</creatorcontrib><description>Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict clinical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients.</description><identifier>ISSN: 0021-9738</identifier><identifier>ISSN: 1558-8238</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI152696</identifier><identifier>PMID: 34523607</identifier><language>eng</language><publisher>ANN ARBOR: Amer Soc Clinical Investigation Inc</publisher><subject>Adolescent ; Adult ; Child ; Female ; Humans ; Iodine Radioisotopes ; Life Sciences & Biomedicine ; Medicine, Research & Experimental ; Oncogenes ; Research & Experimental Medicine ; Science & Technology ; Thyroid Cancer, Papillary ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - genetics</subject><ispartof>The Journal of clinical investigation, 2021-09, Vol.131 (18), Article 152696</ispartof><rights>COPYRIGHT 2021 American Society for Clinical Investigation</rights><rights>2021 American Society for Clinical Investigation 2021 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000705538200006</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c579t-c1aa12ee002d04495fff7bd4948aa711c0c7e6d67789c69ad41f83df6ff64e8e3</citedby><cites>FETCH-LOGICAL-c579t-c1aa12ee002d04495fff7bd4948aa711c0c7e6d67789c69ad41f83df6ff64e8e3</cites><orcidid>0000-0002-8427-6869 ; 0000-0002-1677-5228 ; 0000-0002-3952-881X ; 0000-0002-8497-3138</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439585/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439585/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34523607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Franco, Aime T.</creatorcontrib><creatorcontrib>Ricarte-Filho, Julio C.</creatorcontrib><creatorcontrib>Laetsch, Theodore W.</creatorcontrib><creatorcontrib>Bauer, Andrew J.</creatorcontrib><title>Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer</title><title>The Journal of clinical investigation</title><addtitle>J CLIN INVEST</addtitle><addtitle>J Clin Invest</addtitle><description>Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict clinical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Child</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine, Research & Experimental</subject><subject>Oncogenes</subject><subject>Research & Experimental Medicine</subject><subject>Science & Technology</subject><subject>Thyroid Cancer, Papillary</subject><subject>Thyroid Neoplasms - drug therapy</subject><subject>Thyroid Neoplasms - genetics</subject><issn>0021-9738</issn><issn>1558-8238</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkl2LEzEUhoMobq1e-AdkQBBFZk1mkknmRliKH5WFwvpxG9LkpBOZJt1JZnX_vRm6li30YslFQs7zvjmcvAi9JPicEF59-LZYElY1bfMIzQhjohRVLR6jGcYVKVteizP0LMbfGBNKGX2KzmrKqrrBfIauVl6HDXgo4w60s04Xzndu7ZILPh-L1EGRBlBpCz4VwRbK3CivwRQ7ME6lIStSdzsEZwo9FYbn6IlVfYQXd_sc_fz86cfia3m5-rJcXFyWmvE2lZooRSqA3KTBlLbMWsvXhrZUKMUJ0VhzaEzDuWh10ypDiRW1sY21DQUB9Rx93PvuxvUWjM79DaqXu8Ft1XArg3LyuOJdJzfhRgpat0ywbPD2zmAI1yPEJLcuauh75SGMUVaMVy3FpBUZfb1HN6oH6bwN2VFPuLzIHWZI5InOUXmCmqabnw8erMvXR_z5CT4vA1unTwreHQkyk-Bv2qgxRrn8fvVwdvXrmH1zj-1A9amLoR-nEMSTpnoIMQ5gD-MmWE5ZlIcsZvbV_f85kP_DlwGxB_7AOtioHeT4HDCMMceM1aLKJ9wsXFJTO4sw-pSl7x8urf8Berf3Rw</recordid><startdate>20210915</startdate><enddate>20210915</enddate><creator>Franco, Aime T.</creator><creator>Ricarte-Filho, Julio C.</creator><creator>Laetsch, Theodore W.</creator><creator>Bauer, Andrew J.</creator><general>Amer Soc Clinical Investigation Inc</general><general>American Society for Clinical Investigation</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8427-6869</orcidid><orcidid>https://orcid.org/0000-0002-1677-5228</orcidid><orcidid>https://orcid.org/0000-0002-3952-881X</orcidid><orcidid>https://orcid.org/0000-0002-8497-3138</orcidid></search><sort><creationdate>20210915</creationdate><title>Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer</title><author>Franco, Aime T. ; Ricarte-Filho, Julio C. ; Laetsch, Theodore W. ; Bauer, Andrew J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-c1aa12ee002d04495fff7bd4948aa711c0c7e6d67789c69ad41f83df6ff64e8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Child</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine, Research & Experimental</topic><topic>Oncogenes</topic><topic>Research & Experimental Medicine</topic><topic>Science & Technology</topic><topic>Thyroid Cancer, Papillary</topic><topic>Thyroid Neoplasms - drug therapy</topic><topic>Thyroid Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Franco, Aime T.</creatorcontrib><creatorcontrib>Ricarte-Filho, Julio C.</creatorcontrib><creatorcontrib>Laetsch, Theodore W.</creatorcontrib><creatorcontrib>Bauer, Andrew J.</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Franco, Aime T.</au><au>Ricarte-Filho, Julio C.</au><au>Laetsch, Theodore W.</au><au>Bauer, Andrew J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer</atitle><jtitle>The Journal of clinical investigation</jtitle><stitle>J CLIN INVEST</stitle><addtitle>J Clin Invest</addtitle><date>2021-09-15</date><risdate>2021</risdate><volume>131</volume><issue>18</issue><artnum>152696</artnum><issn>0021-9738</issn><issn>1558-8238</issn><eissn>1558-8238</eissn><abstract>Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict clinical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients.</abstract><cop>ANN ARBOR</cop><pub>Amer Soc Clinical Investigation Inc</pub><pmid>34523607</pmid><doi>10.1172/JCI152696</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-8427-6869</orcidid><orcidid>https://orcid.org/0000-0002-1677-5228</orcidid><orcidid>https://orcid.org/0000-0002-3952-881X</orcidid><orcidid>https://orcid.org/0000-0002-8497-3138</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9738 |
| ispartof | The Journal of clinical investigation, 2021-09, Vol.131 (18), Article 152696 |
| issn | 0021-9738 1558-8238 1558-8238 |
| language | eng |
| recordid | cdi_gale_infotracacademiconefile_A677401852 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Adult Child Female Humans Iodine Radioisotopes Life Sciences & Biomedicine Medicine, Research & Experimental Oncogenes Research & Experimental Medicine Science & Technology Thyroid Cancer, Papillary Thyroid Neoplasms - drug therapy Thyroid Neoplasms - genetics |
| title | Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T18%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oncogene-specific%20inhibition%20in%20the%20treatment%20of%20advanced%20pediatric%20thyroid%20cancer&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Franco,%20Aime%20T.&rft.date=2021-09-15&rft.volume=131&rft.issue=18&rft.artnum=152696&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI152696&rft_dat=%3Cgale_pubme%3EA677401852%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2572940198&rft_id=info:pmid/34523607&rft_galeid=A677401852&rfr_iscdi=true |